Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Visit old site
Home Print this page Email this page Small font size Default font size Increase font size
Users Online: 1075


 
 Table of Contents  
CASE REPORT
Year : 2015  |  Volume : 7  |  Issue : 3  |  Page : 114-118

Left ventricular aneurysm and ventricular tachycardia as initial presentation of cardiac sarcoidosis


Department of Cardiology, Saint Michael's Medical Center, Newark, New Jersey, USA

Date of Web Publication25-Mar-2015

Correspondence Address:
Mohammad Thawabi
111 Central Avenue, Newark, New Jersey - 07102
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1947-2714.153923

Rights and Permissions
  Abstract 

Context: Cardiac sarcoidosis (CS) is a rare, potentially fatal disease. It has a wide range of clinical presentations that range from asymptomatic electrocardiogram changes to sudden cardiac death. Ventricular aneurysms and ventricular tachycardia are seen late in the disease, and are rarely the presenting manifestation of the disease. Diagnosis of CS is challenging and often missed or delayed. Case Report: We report a 35-year-old patient who presented with sustained ventricular tachycardia and ST-elevation on electrocardiogram. Cardiac catheterization showed normal coronaries and left ventricular aneurysm. Subsequent 2D-echocardiography showed an infiltrative disease pattern. Cardiac MRI was done and showed late gadolinium enhancement in the septum, apex and lateral wall. The patient was diagnosed with cardiac sarcoidosis and treated with immune suppression and antiarrhythmic agent. In addition underwent AICD implantation. Conclusion: Our case highlights the importance of suspecting cardiac sarcoidosis in young patients presenting with electrocardiogram changes, and present an atypical presentation of this disease.

Keywords: Aneurysm, Cardiac sarcoidosis, ST-elevation, Ventricular tachycardia


How to cite this article:
Jmeian A, Thawabi M, Goldfarb I, Shamoon F. Left ventricular aneurysm and ventricular tachycardia as initial presentation of cardiac sarcoidosis. North Am J Med Sci 2015;7:114-8

How to cite this URL:
Jmeian A, Thawabi M, Goldfarb I, Shamoon F. Left ventricular aneurysm and ventricular tachycardia as initial presentation of cardiac sarcoidosis. North Am J Med Sci [serial online] 2015 [cited 2019 Nov 18];7:114-8. Available from: http://www.najms.org/text.asp?2015/7/3/114/153923


  Introduction Top


Sarcoidosis is a multiorgan, granulomatous disease of unknown etiology. Non-caseating granulomas are the pathological hallmark of this disease. Studies have suggested that it might be an immunological response to unidentified antigenic triggers. The highest incidence is reported in northern European and African individuals, especially in women. In the United States, the annual incidence is estimated to be 10.9 per 100,000 in whites and 35.5 per 100,000 in African Americans. [1],[2]

Cardiac sarcoidosis (CS) can precede, follow, or occur simultaneously with other organs involvement. However, isolated cardiac involvement can occur. Symptomatic cardiac involvement is seen in around 5% of patients with sarcoidosis. Autopsy studies estimate the prevalence of cardiac involvement to be at least 25% of the patients with sarcoidosis. [2] Imaging studies with late gadolinium enhancement-cardiac magnetic resonance (LGE-CMR) show asymptomatic cardiac involvement in 19-25.9% of patients with extra-cardiac sarcoidosis. [3],[4],[5] CS alters the prognosis for those who are affected, and accounts for as many as 13-25% of deaths from sarcoidosis. [2]


  Case Presentation Top


A 35-year-old African American female, with a history of pulmonary sarcoidosis, presented to the emergency department with a 1-hour history of palpitations and light headedness. No chest pain, shortness of breath, loss of consciousness, other significant symptoms, or similar previous episodes were reported. She was diagnosed with pulmonary sarcoidosis 3 years ago by mediastinal lymph node biopsy. She denied taking any medications. No history of smoking, drinking, or drug abuse was reported.

On examination, she was alert and oriented. Her vital signs showed a heart rate of 224 beats/minute, blood pressure of 138/92 mmHg, respiratory rate of 18, temperature of 98.2, and oxygen saturation of 99% on room air. No significant findings were found on physical examination. 12-lead electrocardiogram (EKG) showed a wide-complex tachycardia, ventricular rate of 225/minute, extreme axis, right-bundle pattern in lead V1, and Q-waves in the lateral leads. A decision was made to electively cardiovert the patient. Sinus rhythm was successfully restored, and amiodarone drip was started. Subsequent EKG showed normal sinus rhythm and ST-segment elevations in the lateral leads. Hence, a decision was made to send the patient for emergent cardiac catheterization. Coronary angiogram did not reveal any radiological evidence of coronary artery disease. Left ventriculography showed global left ventricular hypokinesis with an estimated ejection fraction (EF) of 35%. Additionally, an anteroapical segment aneurysm was identified [Figure 1].
Figure 1: Left ventriculography, right-anterior-oblique cranial view: Anteroapical segment aneurysm

Click here to view


2D-Echocardiogram showed dilated left ventricle with moderate concentric hypertrophy and an echogenicity involving the basal to mid septum, consistent with an infiltrative disease [Figure 2]. Due to the high likelihood of an underlying CS, a CMR with gadolinium enhancement was done and showed thickening of the left ventricular myocardium, seen particularly in the septum, and decreased EF of 40%. Delayed images showed diffuse, patchy, transmural and subepicardial gadolinium enhancement involving the septum, apex and lateral wall [Figure 3] and [Figure 4]. Additionally, an anteroapical wall ventricular aneurysm was seen [Figure 5].
Figure 2: 2D-Echocardiogram, parasternal long axis view: Dilated left ventricle, moderate concentric hypertrophy. Echogenicity in the basal to mid septum

Click here to view
Figure 3: LGE-CMR, two-chamber view: Diffuse patchy transmural as well as subepicardial late gadolinium enhancement

Click here to view
Figure 4: LGE-CMR, shortaxis view: Diffuse patchy transmural as well as subepicardial late gadolinium enhancement

Click here to view
Figure 5: CMR, two-chamber view, T2: Aneurysm in anteroapical
ventricular wall with evidence of dyskinesia


Click here to view


The patient was diagnosed with cardiac sarcoidosis complicated by ventricular aneurysm formation and ventricular tachycardia. She was switched to oral amiodarone and underwent AICD implantation for secondary prevention of life-threatening arrhythmias. The patient was discharged from the hospital with no further arrhythmias during her stay.


  Discussion Top


The clinical presentations of CS are wide and variable; they can range from asymptomatic electrocardiographic changes to sudden cardiac death. The clinical manifestations are usually related to the location and extent of granulomas.

Electrophysiological abnormalities in cardiac sarcoidosis include conduction abnormalities and ventricular and supraventricular arrhythmias. Conduction abnormalities occurin up to 62% of patients during the disease course and usually present as complete heart block. Ventricular arrhythmias occur in up to 42% of patients during the disease course. They usually result from direct granulomatous involvement of the myocardium and might persist despite medical treatment. [2] Unlike the conduction abnormalities that develop in the inflammatory phase of the disease, ventricular arrhythmias are not closely related to the disease activity, and frequently develop in the advanced stages. [6] Supraventricular arrhythmias occur less frequently than ventricular arrhythmias. They are usually the result of atrial dilatation due to left ventricular dysfunction, cor-pulmonale, or direct granulomatous involvement of the atria. Other findings on the electrocardiogram include pseudoinfarction patterns that mimic myocardial infarction and non-specific repolarization changes.

Heart failure occurs in 10%-30% of the patients during the disease course. Ventricular dysfunction can be systolic, diastolic, or both. Ventricular aneurysms result from direct myocardial involvement, which unlike ischemic aneurysms; do not follow a coronary artery distribution. Pericardial effusions are seen in up to 19% of patients. Rarely, symptomatic pericarditis, constrictive pericarditis, or cardiac tamponade can be seen. Mitral valve regurgitation is the most common encountered valvular lesion in CS, and is usually the result of papillary muscles dysfunction or direct granulomatous involvement of the valve leaflets. [2] Sudden cardiac death is the most feared cardiac manifestation of CS and usually results from either ventricular arrhythmias or complete heart block. It is the most common cause of death in CS and responsible for 24%-64% of all deaths in the USA. [2] Progressive heart failure is the second-most common cause of death and accounts for up to 25% of all the deaths in CS. [7] The most important independent predictors of mortality in CS are the New York Heart Association (NYHA) functional class, left ventricular end diastolic diameter, and presence of sustained VT. [8] Furthermore, patients presenting with ventricular aneurysm have been found to have a worse prognosis. [9]

The diagnosis of CS is challenging and often missed or delayed. Heart Rhythm Society expert consensus recommendations in July, 2014, identify CS by two pathways. The first requires the presence of non-caseating granulomas on histological examination of myocardial tissues with no other alternative cause. The second requires the presence of a histological diagnosis of extra-cardiac sarcoidosis, excluding other causes of cardiac manifestations, and one of the followings: steroid and/or immunosuppressant responsive cardiomyopathy or heart block, unexplained reduced LVEF (<40%), unexplained sustained (spontaneous or induced) VT, Mobitz type II second-degree heart block or third-degree heart block, patchy uptake on dedicated cardiac 18F-Flurodeoxyglucose-Positron Emission Tomography (FDG-PET), LGE-CMR, or a positive gallium uptake. [10]

CMR has an excellent sensitivity and specificity for the diagnosis of CS despite the lack of pathognomonic patterns. [10] The appearance of CS on CMR depends on the disease stage. In the acute setting, inflammation and edema are demonstrated by myocardial thickening and increased T2 signal with a subepicardial or midmyocardial enhancement patterns. In the chronic setting, granulomas cause focal areas of myocardial thinning resulting from scar formation. [11] This is mostly seen as delayed contrast enhancement in areas of granuloma and scar formation that is frequently patchy and nodular. The myocardial lesions are predominantly localized to the basal and subepicardial myocardium. This is atypical for myocardial infarction, which typically shows preferential hyper-enhancement of the subendocardial layer. [12] Similar to CMR, no pathognomonic findings for CS are seen on FDG-PET. CS is most typically associated with focal FDG uptake either in isolation or on a background of mild diffuse uptake with or without resting perfusion defects and wall motion abnormalities. Concomitant use of PET perfusion tracers can help exclude significant coronary artery obstructive disease. In addition, FDG-PET can detect reversible stages of CS.

Lung or lymph node biopsies are usually done first in patients with extra-cardiac sarcoidosis due to their higher yield and lower risks. However, in cases of isolated CS or negative extra-cardiac biopsies, endomyocardial biopsy may be required to confirm the diagnosis. Non-caseating granulomas are found in less than 25% of patients due to the focal nature of the disease. Results can be enhanced by utilizing electrophysiological, PET, or CMR image-guided biopsies. [10]

Corticosteroids might halt the progression of cardiac disease and improve survival by slowing the progression of inflammation and fibrosis. [7] Superior results might be achieved if they are initiated early in the course of the disease. [2],[8] They aremost beneficial in CS patients with Mobitz-II or third-degree heart blocks, [13] frequent ventricular ectopy, non-sustained VT or sustained ventricular arrhythmias in the presence of an evidence of myocardial inflammation (Class IIa recommendations). [10],[14] High dose prednisone (60-80 mg daily) is generally prescribed initially. [15] Nevertheless, lower initial doses (< = 30 mg daily) can be used without effecting long-term prognosis. [8] Prednisone can be gradually tapered, once the disease is responding, over a period of six months and eventually discontinued. [15] Other immunosuppressive agents, such as infliximab, methotrexate, azathioprine, or cyclophosphamide, can be used in patients who can not tolerate or do not respond to prednisone therapy. However, data regarding their use is limited. [2]

Atrial and ventricular arrhythmias in patients with CS can be controlled with beta-clockers, calcium channel blockers, sotalol, dofetilide, and amiodarone. Class I agents are not recommended due to their adverse outcomes in patients with structural heart disease. Stepwise approach can be used in the management of ventricular arrhythmias; initial treatment with immunosuppression is followed by anti-arrhythmic medications, and finally catheter ablation in refractory or incessant cases (Class IIa recommendation). [10],[16] VT/VF storm can be managed with combination therapy of anti-arrhythmic agents, usually amiodarone, and immunosuppression.

Cardioverter-defibrillator implantation is recommended in patients with spontaneous sustained ventricular arrhythmias, cardiac arrest, or in patients with LVED < = 35% despite optimal medical therapy and immunosuppression (Class I recommendation). ICD can be useful in patients with an indication for permanent pacemaker implantation, unexplained syncope or near syncope that is felt to be arrhythmic in origin, or inducible sustained ventricular arrhythmias (Class IIa recommendation). ICD can be considered in patients with LVEF of 36-49% and/or RVEF < 40% despite optimal medical therapy for heart failure and a period of immunosuppression (Class IIb recommendation). [10]

Heart failure due to CS is treated in the same way of that of other causes. [2] Patients with advanced heart failure or persistent ventricular arrhythmias not amenable to ablation might be considered for cardiac transplantation. Recipients show better one-year post-transplant survival when compared to cardiac transplant for all other indications. However, CS may recurin the transplanted heart. [15]

Screening for cardiac involvement is vital in patients with biopsy proven extra-cardiac sarcoidosis. This can be done initially by history, 12-lead electrocardiogram (Class I recommendation) and 2D-echocardiogram (Class IIa recommendation). Abnormalities can be investigated by advanced cardiac imaging with CMR or FDG-PET (Class IIa recommendation). Additionally, patients younger than 60 years with unexplained second-degree (Mobitz II) or third-degree AV block can be screened for CS with high resolution CT chest and/or advanced cardiac imaging (CMR or FDG-PET). Positive initial screening command extra-cardiac, if feasible, or image guided endomyocardialbiopsies (Class IIa recommendation). [10]

 
  References Top

1.
Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160:736-55.  Back to cited text no. 1
[PUBMED]    
2.
Kim JS, Judson MA, Donnino R, Gold M, Cooper LT Jr, Prystowsky EN, et al. Cardiac sarcoidosis. Am Heart J 2009;157:9-21.  Back to cited text no. 2
    
3.
Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2013;6:501-11.  Back to cited text no. 3
    
4.
Patel AR, Klein MR, Chandra S, Spencer KT, Decara JM, Lang RM, et al. Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: An observational study. Eur J Heart Fail 2011;13:1231-7.  Back to cited text no. 4
    
5.
Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969-77.  Back to cited text no. 5
    
6.
Banba K, Kusano KF, Nakamura K, Morita H, Ogawa A, Ohtsuka F, et al. Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm 2007;4:1292-9.  Back to cited text no. 6
    
7.
Doughan AR, Williams BR. Cardiac sarcoidosis. Heart 2006;92:282-8.  Back to cited text no. 7
    
8.
Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T, et al. Central Japan Heart Study Group. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001;88:1006-10.  Back to cited text no. 8
    
9.
Miyazawa K, Yoshikawa T, Takamisawa I, Mahara K, Inoue K, Iguchi N, et al. Presence of ventricular aneurysm predicts poor clinical outcomes in patients with cardiac sarcoidosis. Int J Cardiol 2014;177:720-2.  Back to cited text no. 9
    
10.
Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11:1305-23.  Back to cited text no. 10
    
11.
Cummings KW, Bhalla S, Javidan-Nejad C, Bierhals AJ, Gutierrez FR, Woodard PK. A pattern-based approach to assessment of delayed enhancement in nonischemic cardiomyopathy at MR imaging. Radiographics 2009;29:89-103.  Back to cited text no. 11
    
12.
Ichinose A, Otani H, Oikawa M, Takase K, Saito H, Shimokawa H, et al. MRI of cardiac sarcoidosis: Basal and subepicardial localization of myocardial lesions and their effect on left ventricular function. AJR Am J Roentgenol 2008;191:862-9.  Back to cited text no. 12
    
13.
Sadek MM, Yung D, Birnie DH, Beanlands RS, Nery PB. Corticosteroid therapy for cardiac sarcoidosis: A systematic review. Can J Cardiol 2013;29:1034-41.  Back to cited text no. 13
    
14.
Yodogawa K, Seino Y, Ohara T, Takayama H, Katoh T, Mizuno K. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann Noninvasive Electrocardiol 2011;16:140-7.  Back to cited text no. 14
    
15.
Shabetai R. Sarcoidosis and the Heart. Curr Treat Options Cardiovasc Med 2000;2:385-98.  Back to cited text no. 15
    
16.
Jefic D, Joel B, Good E, Morady F, Rosman H, Knight B, et al. Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: Report from a multicenter registry. Heart Rhythm 2009;6:189-95.  Back to cited text no. 16
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Case Presentation
Discussion
References
Article Figures

 Article Access Statistics
    Viewed1494    
    Printed38    
    Emailed0    
    PDF Downloaded203    
    Comments [Add]    

Recommend this journal